Effect of long-term tafamidis treatment on health-related quality of life in patients with transthyretin amyloid cardiomyopathy.

Martha GroganMargot K DavisMaria G Crespo-LeiroMarla B SultanBalarama GundapaneniFranca Stedile AngeliMazen Hanna

Published in: European journal of heart failure (2024)

Tafamidis reduced HRQoL decline in patients with ATTR-CM. Patients continuously treated with tafamidis for 60 months demonstrated stabilized HRQoL. In patients who initially received placebo in ATTR-ACT, tafamidis reduced the decline in HRQoL during the LTE study.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
peritoneal dialysis
prognostic factors
clinical trial
randomized controlled trial
patient reported outcomes
double blind
patient reported
open label
placebo controlled